Prostaglandin E1 encapsulated into lipid nanoparticles improves its anti-inflammatory effect with low side-effect

Area of Science:

• Nanotechnology
• Pharmacology
• Biomedical Engineering

Background:

• Prostaglandin E1 (PGE1) possesses anti-inflammatory properties but is rapidly metabolized in the lungs, limiting its clinical use.
• Intravenous administration of PGE1 leads to rapid inactivation, hindering therapeutic efficacy and causing compliance issues in clinical trials.

Purpose of the Study:

• To develop lipid nanoparticles (PLNs) for improved delivery of Prostaglandin E1 (PGE1).
• To evaluate the anti-inflammatory efficacy and safety of PGE1-loaded lipid nanoparticles (PLNs).

Main Methods:

• High-pressure homogenization was used to prepare PGE1-loaded lipid nanoparticles (PLNs).
• Particle size, zeta potential, and entrapment efficiency were characterized.
• In vitro studies assessed sustained release, inhibition of TNF-alpha expression, and adhesion molecule expression.
• In vivo studies evaluated allergenicity and irritation in animal models.

Main Results:

• Successfully prepared PLNs with a particle size of 68.1±4.7 nm and high entrapment efficiency (92.1±1.3%).
• PLNs demonstrated sustained drug release with minimal initial burst.
• PLNs enhanced PGE1's inhibition of LPS-induced TNF-alpha and reduced lymphocyte-endothelial cell adhesion.
• PLNs showed no allergenicity or irritation in animal models, even at high concentrations.

Conclusions:

• PGE1-loaded lipid nanoparticles (PLNs) represent a viable delivery system for enhancing PGE1's anti-inflammatory effects.
• PLNs offer improved efficacy and a favorable safety profile compared to conventional PGE1 administration.
• This novel PLN system holds potential for treating inflammation-related diseases.